AbCellera Biologics Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
AbCellera Biologics Inc. (ABCL) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 76.17 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- AbCellera Biologics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 76.17M shares, a 6.17% increase year-over-year.
- AbCellera Biologics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 79.14M shares, a 10.00% increase year-over-year.
- AbCellera Biologics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 70.69M shares, a 21.82% increase year-over-year.
- AbCellera Biologics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 71.75M shares, a 22.55% increase year-over-year.
- AbCellera Biologics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 70.92M shares, a 21.75% increase from fiscal 2024.
- AbCellera Biologics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 58.25M shares, a 16.30% increase from fiscal 2023.
- AbCellera Biologics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 50.09M shares, a 323.61% increase from fiscal 2022.
- AbCellera Biologics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 11.82M shares, a 1201.62% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 76.17M shares 10-Q · filed 2026-08-05 | 77.66M shares 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 79.14M shares 10-Q · filed 2026-05-11 | ||||
| 2025-12-31 | 70.92M shares 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | 70.69M shares 10-Q · filed 2025-11-06 | 71.46M shares 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 71.75M shares 10-Q · filed 2026-08-05 | 71.85M shares 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 71.95M shares 10-Q · filed 2026-05-11 | ||||
| 2024-12-31 | 58.25M shares 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | 58.03M shares 10-Q · filed 2025-11-06 | 58.54M shares 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 58.55M shares 10-Q · filed 2025-08-07 | 58.80M shares 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 59.06M shares 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | 50.09M shares 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | 50.08M shares 10-Q · filed 2024-11-04 | 50.54M shares 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | 50.71M shares 10-Q · filed 2024-08-06 | 50.78M shares 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | 50.84M shares 10-Q · filed 2024-05-07 | 2.97M shares 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | 11.82M shares 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | 11.41M shares 10-Q · filed 2023-11-02 | 10.91M shares 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | 48.68M shares 10-Q · filed 2023-08-03 | 11.94M shares 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | 50.84M shares 10-Q · filed 2023-05-04 | 2.97M shares 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 908.41K shares 10-K · filed 2024-02-20 | ||||
| 2021-09-30 | 44.85M shares 10-Q · filed 2022-11-08 | 0.00 shares 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | 47.22M shares 10-Q · filed 2022-08-09 | 0.00 shares 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | 0.00 shares 10-K · filed 2023-02-21 | ||||
| 2020-09-30 | 121.85M shares 10-Q · filed 2021-11-10 | ||||
| 2020-03-31 | 15.95M shares 10-Q · filed 2021-05-14 | ||||
| 2019-12-31 | 58.41M shares 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |